However, no statistically significant difference on tumor growth was found between the combination of tumor-targeted HDAC6KD and anti-PD-1 relative to each individual arm, indicating that the abrogation of HDAC6 in SM1-derived tumors was not enough to further improve the anti-tumor effect of the anti-PD-1 blockade. This evidence concerns the gene HDAC6 and neoplasm.